Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder that leads to cognitive decline, memory loss, and behavioral changes, profoundly impacting the quality of life. The diagnosis of AD is often delayed until the disease has reached an advanced stage, at which point significant brain damage has already occurred. Early detection of Alzheimer's is crucial for effective intervention, especially as emerging therapies aim to slow disease progression and provide symptomatic relief. Traditionally, Alzheimer’s disease diagnosis has relied on clinical assessments, neuroimaging, and postmortem brain tissue analysis, but these methods often fail to detect the disease at its earliest, most treatable stages.
Received: 01 October, 2024, Manuscript No. ; Editor Assigned: 03 October, 2024, PreQC No. ; Reviewed: 14 October, 2024, QC No. ; Revised: 21 October, 2024, Manuscript No. ; Published: 28 October, 2024, DOI: 10.37421/2155-9929.2024.15.666.
HTML PDFShare this article
Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report
